Humalog® Mix25™ offers better mealtime glycemic control in patients with type 1 or type 2 diabetes

Diabetes and Metabolism

Volumn 26, Issue 6, 2000, Pages 481-487

  Malone, J K ^a   Yang, H ^a   Woodworth, J R ^a   Huang, J ^a   Campaigne, B N ^a   Halle, J P ^a   Yale, J F ^a   Grossman, L D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Pre meal Humalog Mix25; Type 1 and type 2 diabetes mellitus

Indexed keywords

INSULIN LISPRO; MIX25; MIX75/25; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; ADULT; BLOOD; COMPARATIVE STUDY; DIET RESTRICTION; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 0034352005     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. The human insulin analogue insulin lispro
2. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients
3. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment
4. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
5. Neutral protamine lispro: Activity profile of s.c. administration with and without admixture of soluble lispro
6. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation
7. The Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation
8. Improved postprandial glycemic control with humalog® mix75/25™ after a standard test meal in patients with type 2 diabetes mellitus
9. The two-period change-over design and its use in clinical trials
10. The two period Binary response cross-over trial
11. Interval between insulin injection and breakfast in diabetes
12. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics
13. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group
14. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial
15. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus
16. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)
17. Glucose intolerance and 23-year risk of coronary heart disease and total mortality
18. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up